Grufity logoGrufity logo

AXNX

65.79USD+0.26(+0.40%)Market Closedas of 07 Dec 2022, 09:36 am

Axonics Modulation Technologies Inc

Market Summary

USD65.79+0.26Market Closedas of 07 Dec 2022, 09:36 am
0.40%

AXNX Alerts

AXNX Stock Price

RSI Chart

Valuation

Market Cap

3.4B

Price/Earnings

-44.26

Price/Sales

15.58

Price/Cashflow

-171.26

MarketCap/EBT

-42.31

Price/Sales

Profitability

EBT Margin

-36.82%

Return on Equity

-17.48%

Return on Assets

-14.89%

Fundamentals

Revenue

Revenue (TTM)

240.9M

Revenue Y/Y

50.03%

Revenue Q/Q

2.04%

Earnings

Earnings (TTM)

-75.5M

Earnings Y/Y

5.79%

Earnings Q/Q

24.21%

Price Action

52 Week Range

38.4179.92
(Low)(High)

Last 7 days

1.4%

Last 30 days

5.3%

Last 90 days

-8.8%

Trailing 12 Months

19.5%

Financial Health

Current Ratio

10.49

Debt/Equity

2e-4

Debt/Cashflow

-181.46

Investor Care

Shares Dilution (1Y)

6.98%

Diluted EPS (TTM)

-1.64

Peers (Alternatives to Axonics Modulation Tech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-15.19% 31.17%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
11.64% -6.61%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
11.18% -17.75%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.66% 2.81%
38.21
3.25
-6.81% -14.96%
61.8B
12.6B
8.58% 10.96%
69.9
5.01
9.56% 51.89%
43.9B
5.4B
5.44% -35.45%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
9.55% 2.62%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.31% -13.25%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-6.98% -2.00%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
14.84% -68.69%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
23.76% 23.16%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
2.27% -17.18%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
15.03% -14.89%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-5.60% -30.91%
-16.43
2.57
-8.79% -175.19%

Financials for Axonics Modulation Tech

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue10.8%241217194180162
Gross Profit13.4%170150129116102
Operating Expenses8.7%249229202188167
  S&GA Expenses8.8%14413211810693
  R&D Expenses-1.9%3637393735
Earnings Before Taxes-0.1%-80.11-80.06-80.01-79.28-72.98
Net Income1.3%-75.53-76.53-80.23-80.07-76.25
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets23.0%632514526548561
  Current Assets43.5%449313307321330
    Cash Equivalents18.7%241203213221229
  Inventory-1.0%5858626570
  Net PPE-1.7%77776
  Goodwill-8.3%8795103106110
Liabilities8.4%8376626671
  Current Liabilities103.8%6130262728
  Long Term Debt-0----
    LT Debt, Current-100.0%-0---
Shareholder's Equity25.5%550438463482490
  Retained Earnings-4.5%-374.93-358.68-337.23-314.57-299.40
  Additional Paid-In Capital17.1%961821812804796
Accumulated Depreciation8.0%77665
Shares Outstanding5.0%4947474646
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations34.6%-12.94-19.78-30.89-47.31-68.84
  Share Based Compensation5.3%3029272522
Cashflow From Investing-777.9%-111.41-12.69-2.43-143.00-142.94
Cashflow From Financing3572.5%1344116171171

Risks

What is the probability of a big loss on AXNX?

72.2%


Probability that Axonics Modulation Tech stock will be more than 20% underwater in next one year

57.4%


Probability that Axonics Modulation Tech stock will be more than 30% underwater in next one year.

49.1%


Probability that Axonics Modulation Tech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AXNX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Axonics Modulation Tech was unfortunately bought at previous high price.

Returns

Cumulative Returns on AXNX

36.9%


3-Year Cumulative Returns

Which funds bought or sold AXNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
702,000
3,646,000
0.01%
2022-11-16
GLENMEDE TRUST CO NA
ADDED
33.44
278,000
701,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-54,000
-
-%
2022-11-15
JANE STREET GROUP, LLC
REDUCED
-69.72
-2,382,000
1,438,000
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
108,000
554,000
-%
2022-11-15
Almanack Investment Partners, LLC.
NEW
-
28,000
28,000
-%
2022-11-15
Neuberger Berman Group LLC
REDUCED
-0.77
10,897,000
57,751,000
0.06%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
568.87
4,373,160
4,971,090
0.01%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
CIBC Private Wealth Group, LLC
NEW
-
487,000
487,000
-%

1–10 of 44

Latest Funds Activity

Are funds buying AXNX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own AXNX

Axonics Modulation Tech News

Nasdaq

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?.4 days ago

Orange County Business Journal

AXNX Fair Value

Recent SEC filings of Axonics Modulation Tech

View All Filings
Date Filed Form Type Document
Nov 09, 2022
10-Q
Quarterly Report
Oct 31, 2022
8-K
Current Report
Sep 20, 2022
4
Insider Trading
Sep 15, 2022
4
Insider Trading
Sep 12, 2022
4
Insider Trading
Sep 09, 2022
4
Insider Trading
Aug 26, 2022
4
Insider Trading

Latest Insider Trading transactions for AXNX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-13
Dearen Danny L.
SOLD
-49,593.6
75.6
-656
See Remarks
2022-09-12
Noblett Karen
SOLD
-2,538,800
78.1578
-32,483
Chief Medical Officer
2022-09-12
Noblett Karen
ACQUIRED
623,335
19.1896
32,483
Chief Medical Officer
2022-09-08
Woock John
ACQUIRED
11,427
1.5236
7,500
Chief Marketing Officer
2022-09-08
Woock John
SOLD
-562,524
75.0032
-7,500
Chief Marketing Officer
2022-09-07
Noblett Karen
SOLD
-747,794
71.5319
-10,454
Chief Medical Officer
2022-08-25
Woock John
SOLD
-547,113
72.9484
-7,500
Chief Marketing Officer
2022-08-18
Lopez Esteban
ACQUIRED
-
-
2,100
-
2022-08-18
Demski David M
ACQUIRED
-
-
2,100
-
2022-08-18
Kiernan Jane E
ACQUIRED
-
-
2,100
-

1–10 of 50

Raymond W. Cohen
520
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Income Statement

2022-09-30
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]    
Net revenue$ 70,384$ 46,913$ 187,784$ 127,155
Cost of goods sold19,12415,71953,08646,828
Gross profit51,26031,194134,69880,327
Operating expenses    
Research and development7,9368,64826,30727,115
General and administrative9,3897,44329,97422,104
Sales and marketing39,75128,112112,19574,451
Amortization of intangible assets2,3172,2167,1125,094
Acquisition-related costs8,2421,27720,4475,691
Total operating expenses67,63547,696196,035134,455
Loss from operations(16,375)(16,502)(61,337)(54,128)
Other income (expense)    
Interest income1,50191,90424
Interest and other expense(1,898)(229)(3,026)(7,528)
Other expense, net(397)(220)(1,122)(7,504)
Loss before income tax (benefit) expense(16,772)(16,722)(62,459)(61,632)
Income tax (benefit) expense(520)528(2,096)3,269
Net loss(16,252)(17,250)(60,363)(64,901)
Foreign currency translation adjustment(12,057)(5,138)(29,625)(6,481)
Comprehensive loss$ (28,309)$ (22,388)$ (89,988)$ (71,382)
Net loss per share, basic (in USD per share)$ (0.34)$ (0.38)$ (1.31)$ (1.53)
Net loss per share, diluted (in USD per share)$ (0.34)$ (0.38)$ (1.31)$ (1.53)
Weighted-average shares used to compute basic net loss per share (in shares)47,208,19244,848,02346,185,20942,436,061
Weighted-average shares used to compute diluted net loss per share (in shares)47,208,19244,848,02346,185,20942,436,061

AXNX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 241,331$ 220,878
Short-term investments108,6820
Accounts receivable, net of allowance for credit losses of $298 and $355 at September 30, 2022 and December 31, 2021, respectively36,96029,044
Inventory, net57,82764,946
Prepaid expenses and other current assets4,5616,449
Total current assets449,361321,317
Property and equipment, net7,1036,915
Intangible assets, net81,787106,469
Other assets7,0857,734
Goodwill86,942105,510
Total assets632,278547,945
Current liabilities  
Accounts payable9,9727,654
Accrued liabilities7,1065,435
Accrued compensation and benefits11,74212,413
Operating lease liability, current portion1,5231,366
Other current liabilities30,5000
Total current liabilities60,84326,868
Operating lease liability, net of current portion7,9609,052
Deferred tax liabilities, net13,95719,217
Other long-term liabilities010,370
Total liabilities82,76065,507
Commitments and contingencies (Note 3)
Stockholders’ equity  
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, par value $0.0001, 75,000,000 and 50,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; 49,479,594 and 46,330,167 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively55
Additional paid-in capital960,627803,559
Accumulated deficit(374,929)(314,566)
Accumulated other comprehensive loss(36,185)(6,560)
Total stockholders’ equity549,518482,438
Total liabilities and stockholders’ equity$ 632,278$ 547,945